摘要
目的:探讨多药耐药(MDR)基因产物LRP、P-gp、GST-π、TopoⅡ在肺癌中的表达及临床相关性。方法:应用单克隆抗体、免疫组化技术S-P法,对70例肺癌标本进行上述4种MDR指标检测。结果:在肺癌组织中LRP、P-gp、GST-π、TopoⅡ表达的阳性率分别为75.7%、70.0%、82.9%、84.3%,其与性别、年龄、部位、临床分期无关(P>0.05);在未分化、小细胞型肺癌中LRP、P-gp、GST-π表达的阳性率明显降低(P<0.05),而TopoⅡ表达的阳性率则升高(P<0.05,低分化型肺癌除外)。结论:LRP、P-gp、GST-π、TopoⅡ在未化疗过的肺癌组织中均有不同程度的高表达,且与肺癌的某些生物学行为有关,联合检测有助于化疗药物的选择及预后的判断。
Objective To investigate the express of lung resistance protein（LRP）, P-giycoprotein（P-gp）, glutathione-s-transferase-π（GST-π） and topoisomerase Ⅱ （Topo Ⅱ） in lung cancer and evaluate its clinical significance. Methods A total of 70 cases with lung cancer tissues were examined by immunohistochemical SP method using monoclonal antibody to their protein. Results The positive rate of LRP, P-gp, GST-π and Topo Ⅱ in lung cancer tissue were 75, 7%, 70.0%, 82.9% and 84. 3% respectively. Their expression was not related to gender, age, position and clinical stage of lung cancer（ P〉 0.05）. Low expression of LRP, P-gp, GST-π was more often associated with non-differentiated and small cell lung cancer, but expression of Topo Ⅱ was high （ P 〈 0.05, except low-differentiated lung cancer）. Conclusion LRP, P-gp, GST-π and Topo Ⅱ are over expressed in various degrees in lung cancer without chemotherapy, and relate to some biology behavior of the cancer. Combining detection is of much benefit to the choice of the drug of chemotherapy and prediction of prognosis.
出处
《实用医学杂志》
CAS
2005年第23期2629-2632,共4页
The Journal of Practical Medicine
